Understanding Women's HIV Prevention Medicine Choices in Malawi
Part of Infections clinical trials.
This study aims to understand why some women in Malawi stopped taking PrEP (a medicine that prevents HIV) and what could help them stay on treatment. Researchers will contact women who started PrEP but missed their appointments to learn about their experiences and barriers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older
- You started taking PrEP (either an injection or daily pill) at one of the participating clinics in Blantyre, Malawi
- You missed your PrEP appointment by at least 3 months and we haven't been able to reach you recently (within the last 2 years)
- You have a working phone number on file so we can contact you
- You speak Chichewa or English
- You did not officially stop PrEP with your doctor's agreement, and you are not known to have transferred to another clinic
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gives long-acting cabotegravir injections (a shot every 2 months) to people at high risk of HIV. It aims to see if this new prevention method works well in real-world settings.
This research studies how two types of long-acting birth control (a shot called cabotegravir and an implant) work in your body after pregnancy, and how they interact with HIV prevention or treatment. The study helps doctors understand the best doses and timing for women like you.
This study looks at how to make it easier for women in Malawi to stay on PrEP after giving birth while breastfeeding. Researchers will check medical records and ask some women to do a short survey and a finger stick blood test.
This study follows pregnant women and their babies to see how well HIV prevention medicines work during pregnancy. It aims to help keep both mother and baby healthy.
This study is testing a new way to find and treat HIV in pregnant women and new mothers in Malawi. It may help prevent passing HIV from mother to baby.
This study helps healthcare providers and clinics deliver long-acting injectable PrEP (a preventive HIV medication given as an injection) more effectively. Researchers will study how clinics can better implement and offer this option to patients who need it.
Hear when a new Long-acting Injectable Cabotegravir for PrEP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.